Literature DB >> 11339519

A comparison of the efficacy and tolerability of meloxicam and diclofenac in the treatment of patients with osteoarthritis of the lumbar spine.

J P Valat1, S Accardo, J Y Reginster, M Wouters, M Hettich, P L Lieu.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of meloxicam compared with diclofenac in patients with osteoarthritis of the lumbar spine.
SUBJECTS: 229 patients with radiologically confirmed osteoarthritis of the lumbar spine. TREATMENT AND METHODS: Once-daily meloxicam 7.5 mg tablet or diclofenac 100 mg slow release tablet. Efficacy and tolerability parameters were assessed at baseline and after 3, 7 and 14 days of treatment.
RESULTS: The two drugs had equal short-term efficacy, with pain on motion of lumbar spine significantly (p<0.05) decreased at Day 3. Secondary efficacy variables were also significantly improved at Days 3, 7 and 14. There were no statistically significant differences between the two drugs, although the global tolerability of meloxicam was significantly better than for diclofenac, as assessed by the investigators (p = 0.0072) and the patients (p = 0.049).
CONCLUSIONS: Meloxicam and diclofenac were equivalent in relieving the acute pain associated with osteoarthritis of the lumbar spine. However, meloxicam was much better tolerated.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11339519     DOI: 10.1007/PL00000218

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  2 in total

1.  Pharmacokinetic properties of low-dose SoluMatrix meloxicam in healthy adults.

Authors:  Azra Hussaini; Daniel Solorio; Clarence Young
Journal:  Clin Rheumatol       Date:  2015-12-05       Impact factor: 2.980

2.  Chinese herbal recipe versus diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial [ISRCTN70292892].

Authors:  Supanimit Teekachunhatean; Puongtip Kunanusorn; Noppamas Rojanasthien; Kanit Sananpanich; Suwalee Pojchamarnwiputh; Sorasak Lhieochaiphunt; Sumalee Pruksakorn
Journal:  BMC Complement Altern Med       Date:  2004-12-13       Impact factor: 3.659

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.